AbbVie Has 2Q Beat Helped By Skyrizi and Rinvoq -- Market Talk
Dow Jones2026/07/31 13:340933 ET - AbbVie reports 2Q results ahead of expectations, JPMorgan analysts say in a research note. The top-line beat was fairly broad based, with Both Skyrizi and Rinvoq modestly ahead of estimates. "On the call, we will be closely listening for any updated expectations on 1) uptake of Skyrizi/Rinvoq (and updated guidance for both) and 2) business development commentary," the analysts say. AbbVie is off 1% in early trading, after lowering its full-year adjusted earnings outlook to account for its acquisition of Apogee Therapeutics. (connor.hart@wsj.com)
(END) Dow Jones Newswires
July 31, 2026 09:34 ET (13:34 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Spot bitcoin ETFs pull in $987 million last week as institutional demand recovers
Silver Price Forecast: XAG/USD dips below $66.00 and hints at a bearish “H&S”
Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well
Swiss pharmaceutical giant Novartis has suffered another clinical trial setback—within one week, the company’s second major drug candidate has failed in a late-stage study. This latest disappointment concerns its potential blockbuster heart disease drug pelacarsen.
Crypto prices
More
